ArticleKidney medicine2026
Diabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rationale & Objective: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) have demonstrated renal and cardiovascular benefits among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). However, their comparative effects on diabetic retinopathy (DR) outcomes in patients with CKD stages 3-4 and T2D remain unclear. This study aimed to demonstrate the effect of SGLT2i vs GLP1RA in this population. Study Design: Population-based, new-user, active comparator cohort study comparing SGLT2i versus GLP1RA initiators. Subjects were divided into 2 cohorts: (1) incident nonproliferative diabetic retinopathy (NPDR) and (2) DR progression cohort. Setting & Study Population: Patients with CKD stages 3-4 and T2D across 3 US health care databases: Optum's de-identified Clinformatics Data Mart Database (2014-2024), Merative MarketScan (2014-2022), and Medicare Fee-for-Service (2014-2020). Selection Criteria for Studies: Adults with a new prescription for either SGLT2i or GLP1RA without prior use in the preceding 365 days. The primary outcomes were incident NPDR and DR progression, identified through ICD-9/10 diagnosis codes and procedural codes for retinopathy treatments. Data Extraction: Exposures, covariates, and outcomes were obtained from structured claims fields. Analytical Approach: Both cohorts were analyzed using propensity score matching (1:1) to control for confounding. Incidence rates (IRs), rate differences, and hazard ratios (HRs) were calculated. Results: After 1:1 propensity score matching, the study included 20,135 matched patient pairs in the incident NPDR cohort and 7,763 matched pairs in the DR progression cohort. For incident NPDR, there was no difference between SGLT2i and GLP1RA groups (IR 29.55 vs 30.38 per 1,000 person-years, respectively; HR 0.98 [95% CI, 0.87-1.10]). Similarly, DR progression was not different between groups (IR 32.73 vs 35.24 per 1,000 person-years; HR 0.92 [95% CI, 0.76-1.12]). Subgroup analyses showed no differences in HRs for both incident NPDR and DR progression across multiple predefined subgroups. Limitations: Potential for residual confounding, outcome misclassification, and limited generalizability to non-U.S. populations. Conclusions: Initiation of SGLT2i was not associated with a different risk of incident NPDR or DR progression compared with GLP1RA among patients with CKD stages 3-4 and T2D. Additional studies with extended follow-up are needed to better characterize long-term retinal safety profiles of these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.